[FRIAM] Papers on asymptomatic transmission and serology

[Steven A Smith]

Good find, thanks!

"you can see a lot just by looking" - yogi berra
> From the 1st link:
>> Producing highly purified preparations containing a high titer of neutralizing antibodies against SARS2-CoV-2 is preferable to convalescent sera given that these are safer and have higher activity. Unfortunately, such preparations will not be available for many months, whereas locally produced convalescent sera could be available much sooner.
>>
>> [...] At this time, we do not know what an effective neutralizing titer would be in a susceptible individual given passive antibody therapy for prophylaxis, and determining this parameter would be part of the study design. Similarly, we do not know what doses would be effective therapeutically. We do know that when convalescent serum was used to prevent measles or mumps the amounts used were in the order of 10–40 cc (10, 11). In contrast, when convalescent serum was used to treat severe disease in soldiers with 1918 influenza, the amounts given were in the hundreds of milliliters (34). These older studies claimed efficacy even though convalescent serum was given without any knowledge of neutralizing titers. Those experiences suggest that even small amounts of antibody may prevent and/or treat infection. Hence, we can anticipate that effective prophylactic doses would be much smaller than therapeutic doses. This makes sense, since the infecting inoculum is likely to be much smaller than the viral burden during severe disease.
>
>
> On 3/23/20 6:15 PM, Steven A Smith wrote:
>> Glen>	The convalescent sera option for containing COVID-19
>> https://www.jci.org/articles/view/138003
>>
>> Barry>  https://www.globalhealthnow.org/2020-03/covid-19s-stop-gap-solution-until-vaccines-and-antivirals-are-ready
>> [...]
>> I didn't see what dosage of plasma is considered remedial or prophylactic.  Is it one-to-one?  A pint per patient?   I think plasma donors can give a pint weekly or more often?